Continuation of Growth Hormone (GH) Replacement in GH-Deficient Patients during Transition from Childhood to Adulthood: A Two-Year Placebo-Controlled Study
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Previous studies have demonstrated beneficial effects of GH replacement, in adults with GH deficiency (GHD), on body composition, physical fitness, and quality of life. These studies, however, concern patients with adult-onset GHD or childhood-onset (CO) patients enrolled several years after withdrawal of initial therapy. So far, the effects of continuation of GH-administration in patients with CO-GHD have not been examined. We studied a group of nineteen young adults (13 males + 6 females; 16-26 yr old; mean age, 20.2 +/- 0.65 yr) with CO-GHD, in a randomized, parallel, double-blind, placebo-controlled trial for 1 yr, followed by an open phase with GH for 1 yr. All patients received GH therapy at the start of study, and trial medication (GH/placebo) was given in a similar dose. Patients randomized to continued GH treatment exhibited no significant changes in any parameters tested, but intra- and interindividual variations in insulin-like growth factor (IGF)-I levels could suggest compliance problems. Discontinuation of GH for 1 yr resulted in a decrease in serum IGF-I, from 422.0 +/- 56.8 to 147.8 +/- 33.4 microg/L, in the placebo group (P = 0.003). After discontinuation of GH for 1 yr, an increase in total body fat (TBF, kg), measured by dual-energy x-ray absorptiometry scan, was seen [placebo: 22.7 +/- 2.7 to 26.5 +/- 2.5 (P = 0.01); GH: 16.2 +/- 2.1 to 17.2 +/- 2.1 (not significant)]. Resumption of GH after placebo was followed by increments in serum IGF-I (microg/L) [from 147.8 +/- 33.4 to 452 +/- 76 (P = 0.001)] and IGF-binding protein 3, as well as in fasting glucose (mmol/L) [4.9 +/- 0.2 vs. 5.3 +/- 0.2 (P = 0.03)]. After resumption of GH lean body mass (kg) increased [52.4 +/- 4.9 vs. 60.7 +/- 5.6 (P = 0.006)]. Likewise, resumption of GH therapy increased thigh muscle volume and thigh muscle/fat ratio, as assessed by computed tomography [muscle volume (cm2/10 mm): 118.2 +/- 11.7 vs. 130.0 +/- 10.9 (P = 0.002); muscle/fat ratio: 1.33 +/- 0.24 vs. 1.69 +/- 0.36 (P = 0.02)]. In conclusion, discontinuation of GH treatment in GHD patients, during the transition from childhood to adulthood, induces significant and potentially unfavorable changes in IGF-I and body composition, both of which are reversed after resumption of GH treatment. By contrast, continuation of GH therapy results in unaltered IGF-I and body composition. We recommend continuation of GH therapy in these patients, to be undertaken in collaboration between pediatricians and adult endocrinologists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review
Carroll, P. V., Christ the members of Growth Hormon, E. R., Bengtsson, B. Å., Carlsson, L., Christiansen, J. S., Clemmons, D., Hintz, R., Ho, K., Laron, Z., Sizonenko, P., et al. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.2.4594 · Cited by 822
Self-citationJørgensen, J. O. L., Møller, J., Laursen, T., Ørskov, H., Christiansen, J. S., & Weeke, J. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb01826.x · Cited by 162 · cited 1×
“GH administration in GHD patients, as well as in obese women, has been reported to induce a decline in circulating T4 levels secondary to stimulation of peripheral conversion of T4 to T3 ( 29 , 30).”
BackgroundSelf-citationWhich adults develop side-effects of growth hormone replacement?
Holmes, S. J., & Shalet, S. M. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb01908.x · Cited by 101 · cited 1×
“This confirms earlier studies in which adverse events are seen more commonly in subjects with AO than with CO-GHD (5, 6, 43 ).”
Result
Cited by
Roubenoff, R., & Hughes, V. A. (2000) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/55.12.m716 · Cited by 685
Consensus statement on the management of the GH-treated adolescent in the transition to adult care
Clayton, P. E., Cuneo, R. C., Juul, A., Monson, J. P., Shalet, S. M., & Tauber, M. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01829 · Cited by 270
Self-citationHoffman, A. R., Kuntze, J. E., Baptista, J., Baum, H. B. A., Baumann, G. P., Biller, B. M. K., Clark, R. V., Cook, D., Inzucchi, S. E., Kleinberg, D., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030346 · Cited by 185
Optimizing GH Therapy in Adults and Children
Drake, W. M., Howell, S. J., Monson, J. P., & Shalet, S. M. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.4.0438 · Cited by 185
Radiation-induced hypopituitarism
Fernandez, A., Brada, M., Zabuliene, L., Karavitaki, N., & Wass, J. A. H. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-08-0231 · Cited by 84
“Significant impairments of QoL in patients with CO-GHD in the transitional period have not been confirmed by all authors, and the effect of GH therapy on this variable remains controversial in transitional patients (Vahl et al .”
BackgroundUlutabanca, H., Hatipoglu, N., Tanriverdi, F., Gökoglu, A., Keskin, M., Selcuklu, A., Kurtoglu, S., & Kelestimur, F. (2014) · Child s Nervous System · doi:10.1007/s00381-013-2334-y · Cited by 31
“GHD causes increased body fat and decreased lean body mass, cardiac dysfunction, decreased exercise capacity, reduced bone mineral density, neuropsychiatric disorders, and decreased quality of life (QOL) [62–64].”
Metadata
- Authors
- Vahl, N.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2000-05-01
- Volume
- 85
- Issue
- 5
- Pages
- 1874-1881
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2018332357
- Cited by
- 125
- References
- 3
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.